MAIA Biotechnology (MAIA) director acquires 38,145 shares of common stock

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Cristian Luput reported open-market purchases of the company’s common stock. On 11/26/2025, he bought 20,000 shares at a price of $1.0808 per share. On 11/28/2025, he purchased an additional 18,145 shares at a weighted average price of $1.1149 per share, with individual trades ranging from $1.1147 to $1.1192. After these transactions, he beneficially owned 437,628 shares of MAIA common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luput Cristian

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/26/2025		P		20,000	A	$1.0808	419,483	D
Common Stock	11/28/2025		P		18,145	A	$1.1149(1)	437,628	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1147 to $1.1192, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

	/s/ Cristian Luput	11/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

The filing reports that director Cristian Luput purchased shares of MAIA Biotechnology, Inc. common stock in open-market transactions on 11/26/2025 and 11/28/2025.

How many MAIA Biotechnology shares did the director buy and at what prices?

Cristian Luput bought 20,000 shares at $1.0808 per share on 11/26/2025, and 18,145 shares at a weighted average price of $1.1149 per share on 11/28/2025, with individual trades between $1.1147 and $1.1192.

What is the directors total MAIA Biotechnology share ownership after these trades?

Following the reported purchases, Cristian Luput beneficially owned 437,628 shares of MAIA Biotechnology common stock, held in direct ownership.

What type of security was involved in the MAIA (MAIA) insider transaction?

The transactions involved common stock of MAIA Biotechnology, Inc. reported in Table I for non-derivative securities. No derivative securities transactions were reported in Table II.

How does the Form 4 describe the pricing of the 11/28/2025 MAIA share purchase?

The Form 4 notes that the $1.1149 price is a weighted average, with shares bought in multiple trades at prices ranging from $1.1147 to $1.1192, and offers to provide full trade details upon request.